No evidence of an association between CYP2D6 polymorphisms among Japanese and dementia with Lewy bodies

被引:14
作者
Furuno, T [1 ]
Kawanishi, C
Iseki, E
Onishi, H
Sugiyama, N
Suzuki, K
Kosaka, K
机构
[1] Yokohama City Univ, Sch Med, Dept Psychiat, Yokohama, Kanagawa 232, Japan
[2] Numazu Cent Hosp, Numazu, Japan
关键词
CYP2D6; polymorphisms; dementia with Lewy bodies; Japanese population; restriction fragment length polymorphism;
D O I
10.1046/j.1440-1819.2001.00793.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Dementia with Lewy bodies (DLB) is the second most frequent degenerative dementia among the elderly, following Alzheimer-type dementia (ATD). An association of DLB with CYP2D6*4, one of the cytochrome P450IID6 (debrisoquine 4-hydroxylase; CYP2D6) gene polymorphisms, was reported previously, but this is controversial. Moreover, these reports have been restricted to Caucasian populations. Therefore, we compared frequencies of CYP2D6*3, *4, and *10 mutant alleles in 17 Japanese DLB patients to those among Alzheimer-type dementia (ATD) patients and healthy controls. Polymerase chain reaction amplification and restriction fragment length polymorphism analyses were used for genotyping, No significant difference of genotype or mutant allele frequencies was detected between DLB, ATD, and healthy controls. The present results do not support the suggestion that the CYP2D6 gene is related to DLB susceptibility, at least in the Japanese population.
引用
收藏
页码:89 / 92
页数:4
相关论文
共 23 条
[1]   ASSOCIATION BETWEEN THE OXIDATIVE POLYMORPHISM AND EARLY-ONSET OF PARKINSONS-DISEASE [J].
AGUNDEZ, JAG ;
JIMENEZJIMENEZ, FJ ;
LUENGO, A ;
BERNAL, ML ;
MOLINA, JA ;
AYUSO, L ;
VAZQUEZ, A ;
PARRA, J ;
DUARTE, J ;
CORIA, F ;
LADERO, JM ;
ALVAREZ, JC ;
BENITEZ, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (03) :291-298
[2]   MUTANT DEBRISOQUINE HYDROXYLATION GENES IN PARKINSONS-DISEASE [J].
ARMSTRONG, M ;
DALY, AK ;
CHOLERTON, S ;
BATEMAN, DN ;
IDLE, JR .
LANCET, 1992, 339 (8800) :1017-1018
[3]   CYP2D6 is associated with Parkinson's disease but not with dementia with Lewy Bodies or Alzheimer's disease [J].
Atkinson, A ;
Singleton, AB ;
Steward, A ;
Ince, PG ;
Perry, RH ;
McKeith, IG ;
Fairbairn, AF ;
Edwardson, JA ;
Daly, AK ;
Morris, CM .
PHARMACOGENETICS, 1999, 9 (01) :31-35
[4]   Lack of relation between genetic polymorphism of cytochrome P-450IID6 and sporadic idiopathic Parkinson's disease [J].
Bordet, R ;
Broly, F ;
Destee, A ;
Libersa, C ;
Lafitte, JJ .
CLINICAL NEUROPHARMACOLOGY, 1996, 19 (03) :213-221
[5]   GENETIC-POLYMORPHISM OF CYTOCHROME-P450 2D6 IN IDIOPATHIC PARKINSON DISEASE AND DIFFUSE LEWY BODY DISEASE [J].
BORDET, R ;
BROLY, F ;
DESTEE, A ;
LIBERSA, C .
CLINICAL NEUROPHARMACOLOGY, 1994, 17 (05) :484-488
[6]   DEBRISOQUINE SPARTEINE HYDROXYLATION GENOTYPE AND PHENOTYPE - ANALYSIS OF COMMON MUTATIONS AND ALLELES OF CYP2D6 IN A EUROPEAN POPULATION [J].
BROLY, F ;
GAEDIGK, A ;
HEIM, M ;
EICHELBAUM, M ;
MORIKE, K ;
MEYER, UA .
DNA AND CELL BIOLOGY, 1991, 10 (08) :545-558
[7]   GENETIC AND METABOLIC CRITERIA FOR THE ASSIGNMENT OF DEBRISOQUINE 4-HYDROXYLATION (CYTOCHROME-P4502D6) PHENOTYPES [J].
DALY, AK ;
ARMSTRONG, M ;
MONKMAN, SC ;
IDLE, ME ;
IDLE, JR .
PHARMACOGENETICS, 1991, 1 (01) :33-41
[8]   Mutation screening in exons 3 and 4 of α-synuclein in sporadic Parkinson's and sporadic and familial dementia with Lewy bodies cases [J].
El-Agnaf, OMA ;
Curran, MD ;
Wallace, A ;
Middleton, D ;
Murgatroyd, C ;
Curtis, A ;
Perry, R ;
Jaros, E .
NEUROREPORT, 1998, 9 (17) :3925-3927
[9]  
HARRINGTON CR, 1994, AM J PATHOL, V145, P1472
[10]  
JOHANSSON I, 1991, EUR J CLIN PHARMACOL, V40, P553